Barclays lowered the firm’s price target on Arvinas (ARVN) to $16 from $32 and keeps an Overweight rating on the shares. The firm says Pfizer reduced vepdeg development while the company’s cash runway is extended to the second half of 2028 on workforce reduction. It has “further derisked” the model, but still sees upside.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas Reports Strong Q1 2025 Results and Strategic Shift
- Arvinas downgraded to Hold at Jefferies after Vepdeg development decision
- Arvinas downgraded to Hold from Buy at Jefferies
- Oppenheimer surprised by ‘hasty’ decision to cull frontline Vepdeg development
- Arvinas reports Q1 EPS $1.14 vs (97c) last year